Supriya Lifescience IPO GMP, Grey Market Premium & Kostak Rates Today:- Here we provided Supriya Lifescience IPO Grey Market Premium, Kostak rates, and Subject to Sauda rates as of today. Supriya Lifescience IPO GMP started and looking strong.
Active pharmaceuticals ingredients manufacturer Supriya Lifescience has decided to launch its IPO on December 16, 2021. The company plans to raise up to Rs 700 crore through its public issue that comprises fresh issuance of shares worth Rs 200 crore and an offer for sale of Rs 500 crore by promoter Satish Waman Wagh. The company has niche product offerings of 38 active pharmaceuticals ingredients (APIs) focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic, as of October 2021. Data Patterns IPO
Supriya Lifescience IPO GMP, Grey Market Premium & Kostak Rates Today
What is Supriya Lifescience IPO GMP Today?
Supriya Lifescience IPO GMP aka grey market premium is Rs 130.
What is Supriya Lifescience IPO Kostak Rates Today?
Supriya Lifescience IPO kostak rate is Rs-.
What is Supriya Lifescience IPO Subject to Sauda Price Today?
Supriya Lifescience IPO subject to sauda rates is Rs 6000.
Supriya Lifescience IPO Expected Returns?
Supriya Lifescience expected return is 40%.
Supriya Lifescience IPO GMP Live Rates day by day with Kotak rates.
Supriya Lifescience IPO GMP Or Grey Market Premium Available Here.
| Date | GMP |
Kostak | Subject to |
| 21 December | Rs 130 | Rs- | Rs 6000 |
| 20 December | Rs 180 | Rs- | Rs 6000 |
| 19 December | Rs 180 | Rs- | Rs 6000 |
| 18 December | Rs 280 | Rs- | Rs 6000 |
| 17 December | Rs 280 | Rs- | Rs- |
| 16 December | Rs 250 | Rs- | Rs- |
| 15 December | Rs 250 | Rs- | Rs- |
| 14 December | Rs 250 | Rs- | Rs- |
| 13 December | Rs 400 | Rs- | Rs- |
| 12 December | Rs- | Rs- | Rs- |
Supriya Lifescience IPO Date & Price Band
| IPO Open: | 16 December 2021 |
| IPO Close: | 20 December 2021 |
| IPO Size: | Rs 700 crore |
| Fresh Issue: | Rs 200 crore |
| Offer for Sale: | Rs 500 crore |
| Face Value: | Rs 2 Per Equity Share |
| Price Band: | Rs- to Rs- Per Share |
| Listing on: | BSE & NSE |
| Retail Quota: | 10% |
| QIB Quota: | 75% |
| NII Quota: | 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
Supriya Lifescience IPO Market Lot
| Minimum Lot Size: | Minimum- Shares for 1 lot |
| Minimum Amount: | Rs- lakh for 1 lot |
| Maximum Lot Size: | Maximum- Shares Shares for 13 lot |
| Maximum Amount: | Rs- for 13 lot |
Supriya Lifescience IPO Reservation :
| Category | Reservation | Shares | Amount |
|---|---|---|---|
| QIB : | 75% | N/A | N/A |
| NII : | 15% | N/A | N/A |
| RII : | 10% | N/A | N/A |
| EMP : | N/A% | N/A | N/A |
| Total : | 100 % | N/A | N/A |
Supriya Lifescience IPO Dates, Allotment & Listing :
Supriya Lifescience IPO Date is 16 December 2021. The allotment date is 23 December 2021 and the IPO may list on 28 December 2021.
| Open Date : | 16 December 2021 |
| Close Date : | 20 December 2021 |
| Allotment Date : | 23 December 2021 |
| Refund Date : | 24 December 2021 |
| Share Credit Date : | 27 December 2021 |
| Listing Date : | 28 December 2021 |
Supriya Lifescience IPO Form
There are two ways to apply in Supriya Lifescience IPO. You can apply for Supriya Lifescience IPO through ASBA available in your bank account. You have to go to your online bank login and select Supriya Lifescience IPO in the Invest section and apply through your bank account. Another option is you can apply for Supriya Lifescience IPO through IPO form download through NSE and BSE. See the Supriya Lifescience IPO Form – Download the NSE Form and BSE Form IPO Form, fill it, and submit it to your bank or your broker.
Supriya Lifescience Financial Report:
| Year | Revenue | Expense | PAT |
| 2021 | Rs 396.2 Crores | Rs 218 Crores | Rs 123.8 Crores |
| 2020 | Rs 322.7 Crores | Rs 213.2 Crores | Rs 73.4 Crores |
| 2019 | Rs 285.8 Crores | Rs 213.1 Crores | Rs 39.4 Crores |
Promoters
- Satish Waman Wagh
Supriya Lifescience IPO Registrar
C-101, 247 Park, 1st Floor,
L.B.S. Marg, Vikhroli West
Mumbai 400 083
Maharashtra, India
Tel: +91 22 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Contact Person: Shanti Gopalkrishnan
SEBI Registration No.: INR000004058
Supriya Lifescience IPO Lead Managers
- ICICI Securities Limited
- Axis Capital Limited
Company Address
Supriya Lifescience Board of Directors
| Name | Designation |
| Satish Waman Wagh | Chairman and Managing Director |
| Smita Satish Wagh | Whole-time Director |
| Saloni Satish Wagh | Whole-time Director |
| Shivani Satish Wagh | Whole-time Director |
| Balasahab Gulabrao Sawant | Whole-time Director |
| Kedar Shankar Karmarkar | Independent Director |
| Bhairav Manojbhai Chokshi | Independent Director |
| Dileep Kumar Jain | Independent Director |
| Dinesh Navnitlal Modi | Independent Director |
| Neelam Yashpal Arora | Independent Director |
About Supriya Lifescience
We are one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients (“APIs”), with a focus on research and development. As of October 31, 2021, we have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. We have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021. We were among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY 2021 in volume terms (Source: CRISIL Report).
Our customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom we have a business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom we have a business relationship for over four years. Our products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA. As of October 31, 2021, we have filed 14 active DMFs with USFDA and eight active CEPs with EDQM, for our API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. For the Fiscals 2019, 2020, 2021 and for the six month period ended September 30, 2021, our export sales accounted for 70.96%, 71.85%77.47% and 73.57%, respectively of our revenue from operations. Similarly, for the Fiscals 2019, 2020,2021 and for the six month period ended September 30, 2021, our domestic sales accounted for 29.04%, 28.15%,22.53% and 26.43%, respectively, of our revenue from operations.
Supriya Lifescience IPO GMP aka Grey Market Premium FAQs:
What is Supriya Lifescience IPO GMP Today?
Supriya Lifescience IPO GMP is Rs- as of today.
What is Supriya Lifescience IPO Kostak Rate Today?
Supriya Lifescience IPO Kostak Rate is Rs- as of today.
What is Supriya Lifescience IPO Subject to Sauda Today?
Supriya Lifescience IPO Subject to Sauda is Rs- as of today.
What is Supriya Lifescience IPO Expected Returns?
Supriya Lifescience IPO Expected Returns is -%.